English, Article edition: Enzyme Replacement Therapy in Orphan and Ultra-Orphan Diseases: The Limitations of Standard Economic Metrics as Exemplified by Fabry-Anderson Disease David F. Moore; Markus Ries; Evelyn L. Forget; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119851
Physical Description
  • article
Language
  • English

Edition details

Title
  • Enzyme Replacement Therapy in Orphan and Ultra-Orphan Diseases: The Limitations of Standard Economic Metrics as Exemplified by Fabry-Anderson Disease
Author
  • David F. Moore
  • Markus Ries
  • Evelyn L. Forget
  • Raphael Schiffmann
Physical Description
  • article
Notes
  • Background: Fabry-Anderson disease is an x-linked deficiency of lysosomal alpha-galactosidase A (GALA), resulting in chronic renal failure, cardiac arrhythmia, hypertrophy, valvular disease, pain (acro-paraesthesiae) and stroke, together with premature mortality. The disease has a significant impact on quality of life (QOL), as illustrated by studies using the EQ-5D. A specific treatment is available for Fabry-Anderson disease consisting of intravenous enzyme replacement therapy (ERT) of the deficient enzyme. The variable clinical efficacy and cost of ERT has resulted in reluctance by some health providers to approve it. Methods: We use the limited QOL data available in the Fabry-Anderson disease literature on ERT to derive standard economic metrics. These were derived by bootstrap estimates of the incremental net benefit (INB) statistics together with a cost-effectiveness acceptability curve relating the willingness to pay to the probability that the INB was >0. The estimates were further developed by adoption of a supplementary Bayesian approach utilising a sceptical and enthusiastic prior of the INB of ERT in Fabry-Anderson disease. Results: ERT for Fabry-Anderson disease is not economically viable by standard health programme evaluation metrics. Based on current ERT costs (year 2005 values), derivation of the INB distribution, and a Bayesian analysis using an enthusiastic and sceptical prior of the INB, an upper ($US350_000 over 1 year) and lower ($US175_000 over 1 year) economic cost, respectively, of ERT was derived. Conclusion: The cost of ERT will always result in a net deficit to society under current costing and ERT efficacy as determined by the QALY metric. The rules of fair cooperation should govern decision making both for ERT in Fabry-Anderson disease and for funding therapeutic advances in other rare diseases belonging to the orphan and ultra-orphan categories.
  • Bayesian-analysis, Cost-utility, Enzyme-stimulants, Fabry's-disease, Glucosylceramidase, Orphan-drugs, Research-and-development
  • RePEc:wkh:phecon:v:25:y:2007:i:3:p:201-208
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment